Home › Uveal Melanoma › Texas › Houston
Uveal Melanoma clinical trials in Houston, TX
5 studies for Uveal Melanoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RecruitingPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Retina Consultants of Texas - (Houston), Houston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- The University Of Texas Md Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecruitingPhase 1
- The University of Texas MD Anderson Cancer Center, Houston
Uveal Melanoma trials in other cities
- Philadelphia, PA7 studies
- Los Angeles, CA6 studies
- Nashville, TN6 studies
- New York City, NY5 studies
- Columbus, OH5 studies
- Denver, CO5 studies
- Boston, MA5 studies
- Scottsdale, AZ5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Aurora, CO4 studies
- Pittsburgh, PA4 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)122 studies
- Metastatic Cancer104 studies
- Colorectal Cancer103 studies
- Ovarian Cancer90 studies
- Acute Myeloid Leukemia86 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer69 studies
- Pancreatic Cancer62 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.